Patents Examined by Timothy R Rozof
  • Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N?-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer
    Patent number: 11091440
    Abstract: Disclosed are malate salts of N-(4-{[6,7-bis(methyloxy)-quinolin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)cyclo-propane-1,1-dicarboxamide, including a (L)-malate salt, a (D)-malate salt, a (DL) malate salt, and mixtures thereof; and crystalline and amorphous forms of the malate salts. Also disclosed are pharmaceutical compositions comprising at least one malate salts of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)-cyclopropane-1,1-dicarboxamide; and methods of treating cancer comprising administering at least one malate salt of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide.
    Type: Grant
    Filed: January 14, 2021
    Date of Patent: August 17, 2021
    Assignee: Exelixis, Inc.
    Inventors: Adrian St. Clair Brown, Peter Lamb, William P. Gallagher
  • Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
    Patent number: 11091439
    Abstract: Disclosed are malate salts of N-(4-{[6,7-bis(methyloxy)-quinolin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, including a (L)-malate salt, a (D)-malate salt, a (DL) malate salt, and mixtures thereof; and crystalline and amorphous forms of the malate salts. Also disclosed are pharmaceutical compositions comprising at least one malate salts of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)-cyclopropane-1,1-dicarboxamide; and methods of treating cancer comprising administering at least one malate salt of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.
    Type: Grant
    Filed: October 14, 2020
    Date of Patent: August 17, 2021
    Assignee: Exelixis, Inc.
    Inventors: Adrian St. Clair Brown, Peter Lamb, William P. Gallagher
  • Solid state crystalline forms of a selective potassium channel modulator
    Patent number: 11091441
    Abstract: The present disclosure provides solid state forms of a selective potassium channel modulator and pharmaceutical compositions comprising the solid state crystalline forms and pharmaceutically acceptable excipients, and methods for preparing and using the solid state forms and the pharmaceutical compositions thereof.
    Type: Grant
    Filed: October 13, 2020
    Date of Patent: August 17, 2021
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Paul Robert Bichler, Jean-Jacques Alexandre Cadieux, Matthew David Tandy, Gregory N. Beatch
  • Solid state forms of Lenvatinib Mesylate
    Patent number: 11084791
    Abstract: The present invention provides a crystalline form of Lenvatinib Mesylate, processes for the preparation of crystalline form of lenvatinib Mesylate and pharmaceutical compositions thereof. The crystalline form of lenvatinib Mesylate designated as Form VN1 is characterized by powder X-ray diffraction pattern. The present invention further provides a process for the preparation of amorphous form of lenvatinib Mesylate. The amorphous form is characterized by powder X-ray diffraction pattern.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: August 10, 2021
    Assignee: DR. REDDY'S LABORATORIES LIMITED
    Inventors: Saladi Venkata Narasayya, Vamsi Krishna Mudapaka, Vishweshwar Peddy
  • Process for producing 5-hydroxymethylfurfural in the presence of an inorganic dehydration and a chloride source
    Patent number: 11084797
    Abstract: The invention relates to a process for converting a feedstock comprising at least one sugar into 5-hydroxymethylfurfural, wherein said feed is brought into contact with one or more inorganic dehydration catalysts and one or more chloride sources in the presence of at least one aprotic polar solvent alone or as a mixture, at a temperature of between 30° C. and 200° C., and at a pressure of between 0.1 MPa and 10 MPa.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: August 10, 2021
    Assignee: IFP Energies nouvelles
    Inventors: Justine Denis, Marc Jacquin, Damien Delcroix
  • Deuterated fezolinetant
    Patent number: 11078203
    Abstract: Deuterated fezolinetant (R)-(4-fluorophenyl)-(8-methyl-3-(3-(methyl-d3)-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]trizolo[4,3-a]pyrazin-7(8H)-yl)methanone: or a pharmaceutically acceptable salt or solvate thereof, as an NK-3 antagonist. Also, methods of modulating NK-3 receptor activity including administering an effective amount of the compound or pharmaceutically acceptable salt or solvate thereof. Additionally, a process for manufacturing the compound or pharmaceutically acceptable salt or solvate thereof.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: August 3, 2021
    Assignee: Ogeda SA
    Inventor: Hamid Hoveyda
  • Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
    Patent number: 11078192
    Abstract: Disclosed are an aromatic acetylene or aromatic ethylene compound, an intermediate, a preparation method, a pharmaceutical composition and a use thereof. The aromatic acetylene or aromatic ethylene compound has a significant inhibitory effect on PD-1 and PD-L1, and can effectively relieve or treat cancers and other related diseases.
    Type: Grant
    Filed: July 4, 2017
    Date of Patent: August 3, 2021
    Inventors: Yuguang Wang, Zusheng Xu, Tianzhi Wu, Min He, Nong Zhang
  • Process for producing 5-hydroxymethylfurfural in the presence of an organic dehydration catalyst and a chloride source
    Patent number: 11078173
    Abstract: The invention relates to a novel process for converting a feedstock comprising at least one sugar into 5-hydroxymethylfurfural, wherein said feedstock is brought into contact with one or more organic dehydration catalysts and one or more chloride sources in the presence of at least one aprotic polar solvent alone or as a mixture, at a temperature of between 30° C. and 200° C., and at a pressure of between 0.1 MPa and 10 MPa.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: August 3, 2021
    Assignee: IFP Energies nouvelles
    Inventors: Justine Denis, Marc Jacquin, Damien Delcroix
  • Heteroaromatic compounds as Vanin inhibitors
    Patent number: 11078182
    Abstract: The present invention encompasses compounds of the formula I which are suitable for the treatment of diseases related to Vanin, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: August 3, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Martin Thomas Fleck, Cedrickx Godbout, Hannes Fiepko Koolman
  • Process for the epoxidation of a tetrasubstituted alkene
    Patent number: 11072593
    Abstract: This invention relates to a process for the epoxidation of a tetrasubstituted alkene such as terpinolene to the corresponding epoxide such as terpinolene epoxide by reacting the tetrasubstituted alkene with performic acid prepared in situ from formic acid and hydrogen peroxide in the presence of at least one buffering agent. Further, the invention relates to the use of an oxidizing agent comprising hydrogen peroxide and formic acid for the in-situ epoxidation of a tetrasubstituted alkene.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: July 27, 2021
    Assignee: BASF AGRO B.V.
    Inventors: Joachim Gebhardt, Michael Rack, Bernd Wolf, Stefan Benson, Roland Goetz, Helmut Kraus
  • Antidiabetic heterocyclic compounds
    Patent number: 11072602
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: July 27, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael Miller, Harry R. Chobanian, Shuwen He, Jinsong Hao, Barbara Pio
  • Substituted heterocycles as antiviral agents
    Patent number: 11058678
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: July 13, 2021
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Joseph Panarese, Samuel Bartlett, Katherine Chong, Yat Sun Or
  • Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
    Patent number: 11058670
    Abstract: Methods and compositions are disclosed for diagnosing a patient suspected of suffering from, and for treating a patient suffering from, a disorder such as hypercortisolemia, metabolic syndrome, pre-diabetes, diabetes, Cushing's syndrome, Cushing's Disease, hyperglycemia secondary to hypercortisolemia, a liver disease, a cardiac disorder, high blood pressure, a blood clotting disorder, a cancer, a psychological disorder, weight gain, a disorder of glucose control, a bone disorder (e.g., osteoporosis), hypogonadism, pseudoacromegaly, pituitary tumors, functional hypercortisolism, ACTH secreting tumors, peripheral neuropathy, dyslipidemia and other disorders. The methods and compositions include administration of a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator (GRM).
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: July 13, 2021
    Assignee: Corcept Therapeutics Incorporated
    Inventor: Andreas Moraitis
  • Oxime ether compounds
    Patent number: 11059784
    Abstract: Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: X is CH or N; Y is CH or N; R1 is —OH or —OP(O)(OH)2; L is —CR3?N—O—CRaRa— or CRaR—O—N?CR3; L2 is a bond, —C(O)—, or S(O)2—; and R2, R3, Ra, m, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: July 13, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alaric J. Dyckman, Ling Li, T. G. Murali Dhar, Hai-Yun Xiao
  • Crystalline form of lenvatinib mesylate and methods thereof
    Patent number: 11059787
    Abstract: The present invention provides a novel crystalline form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate (i.e., lenvatinib mesylate) and pharmaceutical compositions thereof. Methods of preparing such a crystalline form and uses in treatment are also provided.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: July 13, 2021
    Assignee: SHENZHEN BOLAN PHARMACEUTICAL CO., LTD
    Inventor: Xiangguang Xiao
  • Crystalline form of N-[1-(5-cyano-pyridin-2- ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide
    Patent number: 11059803
    Abstract: The present invention relates to crystalline forms of N-[1-(5-cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, pharmaceutical compositions comprising said crystalline forms and their use as T-type calcium channel blockers in the treatment or prevention of diseases or disorders where T-type calcium channels are involved.
    Type: Grant
    Filed: July 4, 2018
    Date of Patent: July 13, 2021
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Bibia Heidmann, Markus Von Raumer
  • Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
    Patent number: 11040027
    Abstract: The invention relates to MKK4 (mitogen-activated protein kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The MKK4 inhibitors selectively inhibit protein kinase MKK4 over protein kinases JNK and MKK7.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: June 22, 2021
    Assignee: Heparegenix GMBH
    Inventors: Wolfgang Albrecht, Stefan Laufer, Roland Selig, Phillip Klövekorn, Bent Präfke
  • Penicinotam derivative, preparation method and use thereof
    Patent number: 11040028
    Abstract: Provided are penicinotam derivatives, a tautomer, a stereoisomer, a racemate, a nonequal mixture of enantiomers, a geometric isomer, a solvate, a pharmaceutically acceptable salt or a prodrug thereof, and a pharmaceutical composition comprising the derivatives. Also provided herein is use of the derivatives and the pharmaceutical compositions in treating diseases caused by inflammation, immune system disorders.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: June 22, 2021
    Assignee: OCEAN UNIVERSITY OF CHINA
    Inventors: Changlun Shao, Meiyan Wei, Yaoyao Jiang
  • Expansile crosslinked polymersome for ph-sensitive delivery of anticancer drugs
    Patent number: 11040009
    Abstract: This disclosure relates to polymersomes comprising a crosslinked polymer and their use as drug delivery vehicles. Specifically, polymersomes comprising a polymer of Formula I: wherein each R is independently C1-6 alkyl; and n is an integer between 1 and 50.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: June 22, 2021
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Xifeng Liu, Michael J. Yaszemski, Lichun Lu
  • Method and an apparatus for recovering furfural
    Patent number: 11040950
    Abstract: In a method and an apparatus furfural is recovered from a steam stream (3) which is formed in a treatment of a pretreated wood based material (1). The pretreated wood based material (1) which comprises at least carbohydrates is treated in a steam treatment stage (2) in which the steam is released. The steam stream (3) which comprises furfural is supplied out from the steam treatment stage (2). A pretreated and steam-treated wood based material (4) which comprises carbohydrates is supplied out from the steam treatment stage (2), and the steam stream (3) is treated in a recovery stage (12a, 12b) for recovering a furfural based fraction (14a,14b).
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: June 22, 2021
    Assignee: UPM-KYMMENE CORPORATION
    Inventors: Juha Tamper, Jere Salminen, Mauno Miettinen, Sami Turunen, Meri Ventola, Vilho Nissinen